Repligen (RGEN) Research & Development (2010 - 2026)

Repligen (RGEN) has 17 years of Research & Development data on file, last reported at $14.5 million in Q1 2026.

• Research & Development for Q1 2026 came in at $14.5 million, up 19.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $55.7 million (up 26.4% YoY), and the FY2025 annual result was $54.2 million, up 25.41% from the prior year.
• Research & Development rose to $14.5 million in Q1 2026 per RGEN's latest filing, from $13.1 million in the prior quarter.
• Over five years, Research & Development peaked at $14.5 million in Q1 2026 and troughed at $9.7 million in Q2 2023.
• A 5-year average of $11.6 million and a median of $11.2 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2024: Research & Development jumped 59.68% in 2022, then fell 8.2% in 2024.
• A 5-year view of Research & Development shows it stood at $11.1 million in 2022, then dropped by 7.45% to $10.3 million in 2023, then gained by 13.53% to $11.7 million in 2024, then increased by 12.36% to $13.1 million in 2025, then advanced by 10.2% to $14.5 million in 2026.
• Business Quant data shows RGEN's Research & Development at $14.5 million in Q1 2026, $13.1 million in Q4 2025, and $14.2 million in Q3 2025.